ABSTRACT: Open fractures become infected despite meticulous debridement and care. Locally applied antibiotics, commonly embedded in polymethylmethacrylate, deliver high doses of drug directly to the fracture site. Direct application of antibiotic powder, which is being applied prophylactically in spine surgery, is a recent interest in the trauma sector, where bacterial biofilms are more prevalent. Traditional antibiotics, such as vancomycin, are poor performers against bacterial biofilms thus are ineffective in delayed treatment. Rifampin is an effective eradicator of Staphylococcal biofilms. Here, a rat model of musculoskeletal trauma was used to evaluate the utility of locally applied rifampin powder for reducing established orthopedic Staphylococcal infections in a delayed treatment scenario that previously indicated the limited use of local vancomycin. By applying rifampin powder directly to the contaminated segmental defect, the number of bacteria, as well as clinical indications of infection, were significantly reduced compared to vancomycin and daptomycin. Considering the Infectious Disease Society of America's recommendation to use rifampin in combination with another antibiotic to reduce the onset of rifampin resistance, rifampin powder was also applied in combination with vancomycin or daptomycin with insignificant changes in eradication performance. No indications of rifampin resistance were identified. Clinical Significance: The use of locally applied rifampin is a promising therapy for mature and tolerant musculoskeletal infections. Published 2018. This article is a U.S. Government work and is in the public domain in the USA. J Orthop Res 36:3136-3141, 2018.
Infection remains a leading complication associated with open musculoskeletal injuries despite current surgical and prophylactic practices. 1 As the severity of trauma increases so does the risk for infection, with severely damaged tissues, diminished blood supply, contact with environmental elements, and the addition of fixation implants playing major roles in the onset of infection. 2 Unresolved infection can lead to an elongated and costly recovery, potentially involving fracture non-union, extensive antibiotic therapy, surgical revisions, and possible amputation of the infected limb. 3, 4 Fracture fixation implants, such as fracture plates and intramedullary nails, increase the risk for infection but are necessary to reduce and stabilize fractures. 5 Current antibiotic treatment protocols for device associated infections involve the use of systemic broad-spectrum antibiotics and implantation of antibiotic loaded polymethylmethacrylate (PMMA). 6 Systemic antibiotics can have poor distribution into the mangled tissues associated with severe trauma, often requiring high, potentially toxic doses to achieve local therapeutic levels. 7 The use of antibiotic loaded PMMA concentrates antibiotic delivery within the wound and has proven to be a useful tool to reduce local infection associated with musculoskeletal trauma. 8 However, as a polymerizing, non-resorbable material, antibiotic choice is limited and subsequent procedures are required to remove it. 9 Antibiotic powder application is currently used to decrease the incidence of surgical site infection. By including vancomycin powder (1-2 g) into the instrumented spinal fusion wound prior to closing, the incidence of surgical site infection has dropped fourfold. 10 However, its use for orthopedic trauma may not be as effective, especially when treatment and fixation is delayed. When a wound is heavily contaminated with a bacterial biofilm, local vancomycin has minimal eradication effect on the bacterial bioburden. 11, 12 To tackle the mature and robust biofilm formed after extended bacterial presence, a different antimicrobial could be more effective.
Rifampin, of the rifamycin class of antimicrobials, is an effective biofilm eradicator in vitro. 13 By targeting bacterial protein synthesis, rifampin's mechanism of action is independent of cellular replication. The Infectious Disease Society of America (IDSA), however, does not recommend the use of rifampin for a mono therapy to reduce the occurrence of spontaneous antimicrobial resistance. Investigators are having positive results in vivo when rifampin is administered systemically in combination with vancomycin or daptomycin. 14, 15 Like vancomycin, both rifampin and daptomycin are available as a pharmaceutical powder and therefore capable of making a rapid translation into local wound application. This study aimed to investigate the utility of rifampin powder, in combination with vancomycin or daptomycin, for reducing bacteria in a musculoskeletal infection model that is recalcitrant to conventionally applied local antibiotics.
METHODS

Antibiotic Efficacy In Vitro
Combinations of antibiotics were evaluated for minimum inhibitory concentration (MIC) using Clinical and Laboratory Standards Institute (CLSI) methods and for minimum biofilm eradication concentration (MBEC) using a modified checkerboard assay using minimum MBEC P&G plates (Innovotech, Alberta, Canada). 13, 16, 17 All antibiotic powders were diluted in sterile deionized water prior to use (vancomycin and rifampin were purchased from Sigma-Aldrich, St. Louis, MO, daptomycin (Cubin) was purchased from Merck Pharmaceuticals, Whitehouse Station, NJ).
Briefly, MIC was measured by combining 5 Â 10 5 CFU/ml UAMS-1 (ATCC 49230), a methicillin-susceptible Staphylococcus aureus isolate from a patient with confirmed osteomyelitis, in Mueller Hinton II broth (MHBII) with vancomycin (0.0625-4 mg/ml), daptomycin (0.03125-2 mg/ml), rifampin (0.00098-0.0625 mg/ml), vancomycin and rifampin (0.0625-4 and 0.00098-0.0625 mg/ml), or daptomycin and rifampin (0.03125-2 and 0.00098-0.0625 mg/ml). Following 18 h of incubation, wells were observed for turbidity. Individual antibiotic MIC was defined as the lowest antibiotic concentration which resulted in a non-turbid/clear well. To measure MBEC, 1 Â 10 6 CFU/ml UAMS-1 in MHBII was added to individual wells of the MBEC well-plates and incubated for 24 h at 37˚C with shaking (150 rpm) and humidity. A 24-h in vitro biofilm is recalcitrant to standard antimicrobial therapies. 13, 18 After incubation, the plate tops, containing biofilm coated pegs, were rinsed in phosphatebuffered saline (PBS), placed in a challenge plate containing increasing concentrations of antibiotic: Vancomycin (0.5-128 mg/ml), daptomycin (0.5-128 mg/ml), rifampin (0.0625-8 mg/ml), vancomycin and rifampin (0.5-128 and 0.0625-8 mg/ml), or daptomycin and rifampin (0.5-128 and 0.0625-4 mg/ml) in MHBII, and incubated for an additional 24 h. Pegs were again rinsed with PBS and sonicated for 15 min at 40 kHz (Branson Ultrasonics Corp, Danbury, CT) into a 96-well plate containing MHBII to disrupt the biofilm and quantitate bacterial recovery. Bacterial viability was determined by plating 5 ml serial dilutions onto MHBII agar 24 h after biofilm disruption.
In Vivo Animal Procedures This study, approved by the Institutional Animal Care and Use Committee of the United States Army Institute of Surgical Research, was conducted in compliance with the Animal Welfare Act, the implementing Animal Welfare Regulations, and the principles of the Guide for the Care and Use of Laboratory Animals, National Research Council. The facility where this research was conducted is fully accredited by AAALC International. Antibiotic powder blends were premixed at identified compositions prior to placing in wound.
A previously reported open fracture segmental defect model in a rat was used to evaluate the effectiveness of antibiotic powders at reducing musculoskeletal infection. 19 Lewis rats (N ¼ 63) (Harlan, Haslett, MI) with an average weight of 339 AE 3 g each received a contaminated segmental defect in their right femur. Briefly, each animal was premedicated with sustained release buprenorphine, anesthetized, and the right hind limb shaved and prepared for sterile surgery with a combination of ethanol and betadine. A lateral incision exposed the femur which was stripped of the periosteum and to which a radiolucent plate was affixed with 6-0.9 mm threaded Kircshner wires. Using a reciprocating saw, a 6-mm segment of the diaphysis was removed (Fig. 1A) . A collagen matrix (30 mg) was prewetted with 7.62 Â 10 5 AE 1.23 Â 10 5 (range 2.39 Â 10 5 -4.63 Â 10 6 ) CFU UAMS-1 immediately prior to its placement in the wound. The wound was sutured and the animal recovered for 24 h. After 24 h, the animals were again anesthetized, the wounds open, debrided of collagen and non-viable soft tissue, and irrigated with 60 cc normal saline (irrigation and debridement; I&D). At this point the animals were randomized to a treatment group (Table 1) . For each powder group, a total of 50 mg antibiotic powder was placed within the defect and wound pocket ( Fig. 1B and C ). This antibiotic dose was sufficient to cover the wound area in a thin layer of antibiotic powder, similar to the vancomycin powder distribution in clinical use, and has shown effectivity when applied early in a model of musculoskeletal infection. 11 The wound was closed TOPICAL ANTIBIOTIC EFFECTIVE AGAINST BIOFILM in layers and the animal was recovered. To replicate clinical protocol, all animals received twice daily broad-spectrum systemic antibiotic (cefazolin; SQ, 5 mg/kg) for 72 h posttreatment placement. 19 Fourteen days following treatment placement, the animals were anesthetized, euthanized with an overdose of pentobarbital (Fatal Plus 1 ), and the femur aseptically harvested and processed for bacterial quantification.
Quantitative Microbiology
Following aseptic harvesting of the hind limb, fixation hardware was removed, the femurs were snap-frozen in liquid nitrogen, pulverized to a fine powder, suspended in sterile normal saline, and vortexed for 1 min. The fixation hardware was placed in sterile normal saline and sonicated for 15 min to remove bacteria from the implant surface. Bacteria bioburden was quantified by plating serial dilutions of the bone or hardware supernatant onto 5% sheep agar (Remel, Lenexa, KS). CFU was normalized to sample weight.
Resistance to rifampin was determined by plating serial dilutions of bone homogenate supernatant from rifampin groups onto plates containing 4 mg/ml rifampin.
Blood Draws
Blood was drawn via the tail vein while the rats were under anesthesia at 6 h, 24 h, 7 days, and 14 days post-treatment to measure systemic antibiotic concentration. Serum was separated from blood by centrifuging the samples at 4,000 rpm for 15 min. Antibiotic concentration was measured using HPLC. 
RESULTS
In Vitro Biofilm Eradication Efficacy
Rifampin has a lower MIC than vancomycin or daptomycin and the antibiotic combinations tested showed indifference to planktonic bacteria (Supplemental Table S1 ). UAMS-1 forms a biofilm after 24 h in vitro (Supplemental Fig. S1 ). Rifampin has a lower MBEC against UAMS-1 biofilms than either vancomycin or daptomycin (Table 2 ). When used in combination, rifampin/vancomycin and rifampin/daptomycin had additive antibiofilm effects compared to rifampin alone, based on modified checkerboard assay.
In Vivo Efficacy of Rifampin Powder
The inclusion of rifampin powder reduced the overall bacteria number when applied 24 h after initial inoculation (Fig. 2) . The inclusion of various doses of rifampin powder alone demonstrated a complete eradication of bacteria within the operative bone in !75% of the animals ( Fig. 2A) . By combining rifampin with either vancomycin or daptomycin, the effectiveness of the antibiotic application diminished slightly, with detectable bacteria found within the wound but at quantities near the threshold (10 (1.8 Â 10 4 -1.7 Â 10 6 ) CFU/g bone tissue, respectively. This indicates that it is the inclusion of the rifampin within the powder application that is reducing the overall bacteria numbers. Simultaneously, the inclusion of rifampin within all treatment groups was able to eliminate most of the bacteria on the fixation implants (Fig. 2B ). There were no indications of rifampin resistance within the monotherapy groups (100R, 55R, and 38R). This being said, although the local treatment was monotherapeutic, each animal received subcutaneous cefazolin BID for 72 h. In addition to the reduction in bacteria within the wound, those animals that received rifampin alone (100R, 55R, and 38R) were the only groups to recover to pre-surgical weight, significantly different from the I&D weight loss of 6.2% (p < 0.05, one-way ANOVA). The I&D group expressed clinical indications of infection (redness, swelling, purulence) at the surgical site in 10/10 animals at the time of tissue harvesting. The 100V and 100D groups expressed similar signs of infection in 7/10 and 3/5 animals, respectively. The inclusion of rifampin reduced any signs of infection in all rifampin groups except for 55RV, 38RV, and 55RD, which each had one animal with clinical signs of infection.
Antibiotics were detectable in the serum after treatment placement, with all antibiotics peaking 6 h after powder application; however, there was significantly more daptomycin in the serum than vancomycin or rifampin (Fig. 3) . After 1 week, the antibiotics within the serum were barely detectable. Upon tissue harvesting, observable rifampin was still present within the wound compared to the other groups, possibly related to the low solubility of rifampin compared to vancomycin and daptomycin.
DISCUSSION
By applying rifampin powder directly to the wound site, bacterial bioburden was nearly eradicated and clinical signs of infection were diminished. In addition, rifampin had lower systemic levels after 6 and 24 h compared to vancomycin and daptomycin, possibly from its poor water solubility causing a slower dissolution from the wound and lengthier diffusion into tissues, as confirmed by the presence of rifampin within the wound at the time of tissue harvesting. As recommended by IDSA, rifampin was combined with a co-delivery antimicrobial powder, which had additive effects in vitro; however, there was a slight but insignificant diminishment of the eradication efficacy of rifampin in vivo. Regardless of the slight reduction of effectiveness of combined therapies, all therapies containing rifampin were able to significantly reduce the bioburden within the wound compared to both vancomycin and daptomycin alone. The in vitro/in vivo discrepancies provide evidence of limited translatability between in vitro and in vivo work. It is well understood that the application of topical antimicrobials achieve higher concentrations at the site of injury compared to systemic administration and without some of the negative effects of long term systemic antibiotic use. 7 PMMA provides multiple days of local antibiotic release and is the standard choice for mechanical stability and space maintenance, however antibiotic choice is limited and materials must be removed else they become a breeding ground for persistent bacteria. 20 Vancomycin is one of the most common antibiotics loaded into PMMA to prevent and combat gram-positive infections. While effective against "free-floating" planktonic bacteria, vancomycin has . Antibiotic interaction can be interpreted four ways: Synergy is described as an FIC 0.5, additive is an 0.5 < FIC 1, indifference in an 1 < FIC 4, and antagonism is an FIC > 4.
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shown to be ineffective against mature Staphylococcal biofilms in vitro and in vivo. 11, 13 Considering PMMA's well-known use for orthopedic infections, investigators have explored the loading of rifampin, a powerful biofilm eradicator, into PMMA for local delivery. When incorporated into PMMA at high concentrations, $10% wt, rifampin reduces infection rate in a rat model of established S. aureus orthopedic infection. 21 However, as a free radical scavenger, rifampin interferes with the normal PMMA polymerization process, thus decreasing normal curing resulting in a pliable and non-rigid PMMA therefore not suitable for prosthetic joint fixation or areas where space-maintenance is key. In lieu of a delivery device, this project aimed to apply rifampin directly to the wound site.
Bacterial biofilms are a predominant feature of musculoskeletal infection, especially in the presence of implants. Secretion of extracellular matrix components, reduced metabolism, and increased inter-microbial communication stabilize the biofilm thus increasing its recalcitrance to host defense systems and traditional antimicrobials. 22 Rifampin has been identified to be a potent biofilm eradicator. 13, 23 Having been used systemically to treat prosthetic joint infections, investigation toward its use locally has only just begun. 23, 24 Inzana et al. identified the benefit of using locally delivered rifampin in combination with vancomycin to diminish bacteria number in a mouse model of orthopedic infection. 20 Local antimicrobial powder application has been introduced as an adjunctive therapy for perioperative antibiotics to decrease the rate of surgical site infection. 10, 25 Currently used prophylactically, the inclusion of vancomycin powder has resulted in up to a fourfold decrease of surgical site infection in spine surgery, a 73% infection reduction in diabetic foot and ankle surgery and is being evaluated for its utility in fracture surgery patients at high risk for infection. [26] [27] [28] If a contaminated open wound is treated early enough, it may be possible to reduce infection by the application of vancomycin powder to the wound. 11 Increasing the time to treat these open wounds escalates the probability of mature biofilm formation and prevention of antibiotic driven eradication. Rifampin powder could be useful when applied to a wound with history of contamination and/or lack of wound coverage for a prolonged period.
This project compared vancomycin powder to both daptomycin and rifampin powders. Daptomycin, a cyclic lipopeptide, maintains in vitro efficacy against most clinically relevant gram-positive pathogens and is effective in patients with prosthetic joint or other orthopedic device infections when delivered systemically. 15, 29, 30 This study, however, concluded that there is a lack of bacteria reduction when vancomycin or daptomycin powder was solely placed directly into the wound of a mature biofilm model. When rifampin was used within the wound, however, there was remarkable decrease in bacteria, confirming rifampin's potential use as an adjunctive local therapeutic to combat biofilm related device associated infections.
This project has its limitations. Therapeutic effects are constricted to a single pathogen and thus fail to adequately express the broad range of microbial pathogens associated with musculoskeletal infection. S. aureus, however, is the most common pathogen responsible for musculoskeletal infection thus it sufficiently represents rifampin powder's use for reducing wound infection. Additionally, although animal models are a useful research tool, animal size and metabolic rate as well as the use of a surgically derived fracture and infection limit therapeutic observations. However, such preclinical models provide valuable information that are not ethically feasible in clinical trials, such as delayed treatment effect. Finally, although a useful screening tool, the use of standard in vitro assays has its place and limitations. An in vitro assay that better mimicked the antibiotic powder administration may have provided more translatable results in vivo.
CONCLUSION
In conclusion, the use of rifampin powder has proved to be a useful tool for reducing mature biofilm infections when standard microbial therapies are ineffective while not increasing spontaneous rifampin resistance. By combining it with a co-delivery agent, no antibiotic resistance is observed and effectiveness is slightly diminished but nonetheless the combination significantly reduces bacteria compared to vancomycin and daptomycin alone. The current availability of rifampin powder eases the translation toward clinical use. However, to fully evaluate the utility of locally applied rifampin powder for musculoskeletal infections, its effect on the local tissue environment and on fracture healing needs to be evaluated. 
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